![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) in HCV G1 Treatment-experienced Patients Achieves
Primary Endpoint with Superior Efficacy at Treatment Week 12 Compared to Retreatment with PR
|
|
|
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Alfredo Alberti1, Wan-Long Chuang2, Robert Flisiak3, Giusseppe Mazzella4, Andrzej Horban5, Tobias Goeser6, Pietro Calistru7, Maria Buti8, Gary Davis9, Yankun Gong10, Claudio Avila11, Jia-Horng Kao12
1Azienda Ospedaliera Università di Padova Univ.degli Studi, Padova, Italy; 2Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 3Medical University, Bialystok, Poland; 4Az.Osp. di Bologna Policl. S.Orsola-Malpighi, Bologna, Italy; 5Klinika Obserwacyjno-Zakazna, SP ZOZ Wojewodzki Szpital Zakazny, Warsaw, Poland; 6Klinik für Gastroenterologie und Hepatologie Universitätsklinik Köln, Germany; 7Centrul de Diagnostic si Tratament Dr. Viktor Babes, Bucharest, Romania; 8Medicina Interna Hospital Vall D'Hebron, Barcelona, Spain; 9Baylor Health, Dallas, Texas, USA; 10Beijing Novartis Pharma Co. Ltd., Beijing, China; 11Novartis Pharma AG, Basel, Switzerland; 12National Taiwan University Hospital, Taipei, Taiwan
![EASL1.gif](../images/042212/042112-4/EASL1.gif)
![EASL2.gif](../images/042212/042112-4/EASL2.gif)
![EASL3.gif](../images/042212/042112-4/EASL3.gif)
![EASL4.gif](../images/042212/042112-4/EASL4.gif)
![EASL5.gif](../images/042212/042112-4/EASL5.gif)
![EASL6.gif](../images/042212/042112-4/EASL6.gif)
![EASL7.gif](../images/042212/042112-4/EASL7.gif)
![EASL8.gif](../images/042212/042112-4/EASL8.gif)
![EASL9.gif](../images/042212/042112-4/EASL9.gif)
![EASL10.gif](../images/042212/042112-4/EASL10.gif)
![EASL11.gif](../images/042212/042112-4/EASL11.gif)
![EASL12.gif](../images/042212/042112-4/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|